复方气管炎片辅助治疗急性支气管炎的疗效观察

Objective To observe the clinical efficacy of compound bronchitis tablets as an adjuvant therapy for acute bronchitis. Methods During the study period(May 2023 to May 2025), a total of 80 eligible patients were enrolled. Using a double-color ball randomization technique, they were equally divided into two groups. One group received conventional Western medicine treatment(control group, n=40), while the other group received conventional Western Medicine treatment combined with oral compound bronchial tablets(observation group, n=40). The recovery process, inflammatory markers, Traditional Chinese Medicine(TCM) syndrome scores, curative effects, and incidence of adverse reactions were compared between the two groups. Results The disappearance times of cough, expectoration, chest tightness, and rales in the observation group were shorter than those in the control group, and the treatment effective rate was higher in the observation group(P<0.05). There was no significant difference in the levels of inflammatory mediators or TCM syndrome scores between the two groups before treatment(P>0.05). After treatment, the levels of C-reactive protein(CRP), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), and the TCM syndrome scores of recurrent cough, heavy and turbid cough sound, and profuse thick sputum in the observation group were all lower than those in the control group(P<0.05). There was no significant difference in the total incidence of gastrointestinal reactions, dizziness, or rash between the two groups(P>0.05). Conclusion The application of compound bronchitis tablets in the treatment of acute bronchitis can accelerate the patients' recovery process, alleviate symptoms, reduce inflammation, and show good efficacy and high safety.